KaloBios CEO retires following drug failures
This article was originally published in Scrip
David W Pritchard, CEO of California's KaloBios, has retired from the company with immediate effect, just days after the company announced its latest clinical failure. The company was not immediately available to comment on whether the timing of Mr Pritchard's retirement was linked to the failure of KB001-A earlier this week (scripintelligence.com, 7 January 2015). KB001-A's failure followed that of KB003 in January 2014. CFO Herb C Cross has been appointed interim CEO pending a search for a permanent replacement for Mr Pritchard.